Chandra Bhagat Pharma Limited reported a 255% increase in net profit to ₹304.61 lakh for the financial year ended March 31, 2026, compared to ₹85.78 lakh in the previous year. Revenue from operations surged 30.9% to ₹11,627.17 lakh from ₹8,880.54 lakh in FY25. The board approved the audited financial results for the half year and year ended March 31, 2026, at a meeting held on May 25, 2026.

Financial Performance

The company's earnings per share (EPS) for the year stood at ₹4.04, up from ₹1.14 in the prior year. Total income from operations rose to ₹11,962.50 lakh for FY26, compared to ₹9,223.91 lakh in FY25. Expenses for the year totaled ₹11,552.01 lakh, an increase from ₹9,107.37 lakh in the previous year.

Balance Sheet and Cash Flows

The company's reserves and surplus increased to ₹2,558.14 lakh as of March 31, 2026, from ₹2,242.40 lakh a year earlier. Cash and bank balances improved significantly to ₹311.06 lakh from ₹66.51 lakh. Trade receivables rose to ₹5,461.70 lakh from ₹3,594.55 lakh, while short-term borrowings decreased to ₹1,393.92 lakh from ₹1,857.65 lakh.

Net cash generated from operating activities was ₹923.57 lakh, a turnaround from a net outflow of ₹570.89 lakh in the previous year. The company utilized ₹43.46 lakh in investing activities and ₹635.57 lakh in financing activities.

Auditor and Compliance

Statutory Auditors M/S A Y & Company issued an unmodified opinion on the audited financial results. The report confirms compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window for directors and designated personnel will open 48 hours after the announcement of the financial results.

Chandra Bhagat Pharma Limited has announced the establishment of a new international office in Dubai, United Arab Emirates, marking a significant step in the company's global expansion strategy. The pharmaceutical company informed BSE Limited about this development on April 1, 2026, in compliance with Regulation 30 of SEBI listing requirements.

Office Establishment Details

The new Dubai office represents a strategic move to strengthen the company's international presence and tap into global markets. The facility will serve as an International Business/Representative Office, positioning the company to better serve international clients and partners.

Strategic Objectives

The establishment of the Dubai office aligns with Chandra Bhagat Pharma Limited's strategic growth plans and serves multiple business objectives:

• Expand global footprint in international pharmaceutical markets
• Enhance export opportunities and international trade capabilities
• Strengthen relationships with international clients and business partners
• Facilitate better market access in the Middle East and North Africa region

Regulatory Compliance and Documentation

The company has obtained its Certificate of Formation from the Sharjah Media City Free Zone Authority (Shams), established pursuant to Amiri Decree No. 11 for the year 2017. The certificate confirms the formation of Chandra Bhagat Pharma Limited Branch with formation date of March 31, 2026.

Director Pranav H Bhagat (DIN No. 00156362) signed the regulatory filing, ensuring compliance with all applicable listing obligations and disclosure requirements. The company has satisfied all requirements under the rules and regulations of Sharjah Media City Free Zone Authority for the establishment of the branch office.

Business Impact

This international expansion initiative represents Chandra Bhagat Pharma Limited's commitment to enhancing its global business operations and market reach. The Dubai office is expected to serve as a key hub for the company's international activities, facilitating improved access to Middle Eastern and global pharmaceutical markets while supporting the company's long-term growth strategy.